Skip to content

Neural Correlates of Acute Pain Dynamics

The Neural Correlates of and Effects of Methylphenidate on Acute Pain Dynamics

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05669924
Enrollment
40
Registered
2023-01-03
Start date
2022-09-19
Completion date
2024-04-26
Last updated
2024-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

Mesolimbic system, Dopamine circuits, Psychophysics

Brief summary

This work aims to study the neural correlates and determinants of pain dynamics related to changes in a noxious stimulus.

Interventions

DRUGMethylphenidate

0.35 mg/kg methylphenidate will be administered after baseline testing and 45 min-1 hr before post-intervention testing.

DRUGPlacebo

Placebo for methylphenidate

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS)
CollaboratorNIH
Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

\-

Exclusion criteria

* Pregnant * History of chronic pain * History of neurological diagnosis * History of psychiatric diagnosis

Design outcomes

Primary

MeasureTime frameDescription
Effect of methylphenidate on acute pain dynamics6 monthsWe will compare acute pain dynamics-i.e., the time series of pain visual analog scale ratings (0-100, where 0 = no pain and 100 = worst pain imaginable) obtained while delivering a changing noxious stimulus-during the methylphenidate condition to that of the placebo condition.
Nucleus accumbens activation with acute pain dynamics6 monthsWe will regress the time course of nucleus accumbens BOLD activity onto the latent time series obtained from our valence competition model. This will be supported by regressing the nucleus accumbens time course onto the pain VAS time course, allowing our findings to be compared to standard analyses in the literature.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026